MaaT Pharma Aktie

NeuKaufen Kaufen Verkaufen Verkaufen

7,90 EUR -0,04 EUR -0,50 %

29.11.2024

STU

7,96 EUR +0,10 EUR +1,27 %

28.11.2024

PAR

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Smartphone

Marktkap.110,31 Mio. EUR

Div. Rendite0,00%

WKNA3C7A5

ISINFR0012634822

Werbung

MaaT Pharma Aktien News

Sortieren:Datum Meistgelesen

10.12.22BusinesswireMaaT Pharma Presents Compelling Consolidated MaaT013 Clinical Data at the 64th ASH Annual Meeting

29.11.22BusinesswireMaaT Pharma To Webcast Investor Meeting in Conjunction with ASH 2022 Conference

08.11.22BusinesswireMaaT Pharma Reports Cash and Revenues for Third Quarter 2022

07.11.22BusinesswireMaaT Pharma Announces Participation in Scientific and Investor Conferences in November

03.11.22BusinesswireMaaT Pharma Announces Oral and Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting

04.10.22BusinesswireMaaT Pharma Appoints Nathalie Corvaïa as Chief Scientific Officer and Strengthens its R&D Activities in Immuno-Oncology

29.09.22BusinesswireMaaT Pharma Publishes its Half Year Results and Provides a Business Overview

08.09.22BusinesswireMaaT Pharma Announces Participation in Three Upcoming Investor Conferences in September

28.07.22BusinesswireMaaT Pharma Reports Cash and Revenues for Second Quarter 2022

02.06.22BusinesswireMaaT Pharma Confirms Positive Results from Completed Phase 1b CIMON Study Evaluating MaaT033 in Blood Cancer Patients

24.05.22BusinesswireMaaT Pharma to Host First Virtual R&D Day on June 7th, 2022

05.05.22BusinesswireMaaT Pharma Reports Cash and Revenues for First Quarter 2022

21.04.22BusinesswireINRAE and MaaT Pharma Build on the Success of their Long-Standing Partnership with the Entry of Drug-Candidate MaaT013 into Phase 3 Clinical Trial

14.04.22BusinesswireMaaT Pharma Publishes its 2021 Annual Results and Provides a Business Overview

07.04.22BusinesswireMaaT Pharma Announces the Initiation of a Phase 2a Investigator-Sponsored Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors for Patients with Melanoma

04.04.22BusinesswireMaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

28.03.22BusinesswireMaaT Pharma Announces First Patient Dosed in Phase 3 ‘ARES’ Trial Evaluating MaaT013 in Patients with Acute Graft-vs-Host-Disease

21.03.22BusinesswireMaaT Pharma Announces the Implementation of a Liquidity Contract with Kepler Cheuvreux

17.03.22BusinesswireMaaT Pharma to Present Promising Clinical Data for Lead Therapeutic Candidate MaaT013 at 48th EBMT Annual Meeting

28.02.22BusinesswireMaaT Pharma Reports Cash and Revenues for Full-Year 2021

08.02.22BusinesswireMaaT Pharma and Skyepharma Have Entered a Partnership to Establish the First Exclusive Microbiome Ecosystem Therapies cGMP Manufacturing Facility in France

24.01.22BusinesswireMaaT Pharma Announces Positive Interim Engraftment Data for Oral Formulation MaaT033 Allowing Early Termination of Phase 1b CIMON Study

17.01.22BusinesswireMaaT Pharma Provides Business Objectives and Expected Milestones for 2022

13.01.22BusinesswireMaaT Pharma Announces Initiation of Coverage of its Stock by KBC Securities, Kempen and Portzamparc/Groupe BNP Paribas

03.01.22BusinesswireMaaT Pharma to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

01.12.21BusinesswireMaaT Pharma Will Host Investor Information Meeting Following Presentation at ASH Conference of Additional Results on MaaT013

MaaT Pharma News

MaaT Pharma News: auf dieser Seite finden Sie alle MaaT Pharma News und Nachrichten zur MaaT Pharma Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch MaaT Pharma News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um MaaT Pharma News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.